The highly mutated and transmissible Omicron (BA. 1) and its more contagious lineage BA.
2 have provoked serious concerns over their decreased sensitivity to the current COVID-19 …

Emerging severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants,
especially the Omicron variant, have impaired the efficacy of existing vaccines and most …

SARS-CoV-2 Omicron variant has presented significant challenges to current antibodies
and vaccines. Herein, we systematically compared the efficacy of 50 human monoclonal …

Neutralizing antibodies (nAbs) are important assets to fight COVID-19, but most existing
nAbs lose the activities against Omicron subvariants. Here, we report a human monoclonal …

SARS-CoV-2 Omicron subvariants have demonstrated extensive evasion from monoclonal
antibodies (mAbs) developed for clinical use, which raises an urgent need to develop new …

SARS-CoV-2 rapidly evolves during the pandemic 1 with many variants of concern (VoCs)
lineages (Supplementary Fig. S1a). Omicron (B. 1.1. 529) and its sub-lineages led to …

In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from
single B cells of the COVID-19–recovered individuals in India who experienced ancestral …

The rapidly spreading Omicron variant is highly resistant to vaccines, convalescent sera,
and neutralizing antibodies (nAbs), highlighting the urgent need for potent therapeutic nAbs …

Antibody therapeutics for the treatment of COVID-19 have been highly successful. However,
the recent emergence of the Omicron variant has posed a challenge, as it evades detection …

Abstract The SARS-CoV-2 B. 1.1. 529 variant (Omicron) contains 15 mutations on the
receptor-binding domain (RBD). How Omicron would evade RBD neutralizing antibodies …